A calcium examination executed with the help of a CT scanner appears to give insight that particular individuals are at average threat of heart diseases will have a heart attack or stroke, according to the study. The examination to identify coronary calcium can aid doctors uncover whether the patients should consume cholesterol-lowering Canadian drugs to decrease their cardiovascular threats, the study authors clarified.
The study, released in the Aug. 19 issue of The Lancet, wanted to identify whether an examination of calcium in the arteries is more beneficial at assessing threat than a blood test which evaluates levels of C-reactive protein, and thus avoid taking and buying Diovan for their blood pressure concerns brought by their heart problems. The study researchers monitored 2,083 individuals for six years. They identified that 13 percent of those with the maximum levels of calcium in their arteries had a heart attack or stroke within that time span. But just 2 percent of those with excessive levels of C-reactive protein and no calcium upsurge had a heart attack or stroke.
Not all are required to undergo a calcium examination, according lead study author Dr. Michael J. Blaha, a cardiology fellow at the Johns Hopkins University School of Medicine. But, he said in a Hopkins news release, "we believe looking for calcification in coronary vessels in certain patients makes sense in order to predict who may benefit from statin therapy, because the test gets right to the heart of the disease we want to treat."
"Our data support recent American Heart Association guidelines, which say it is reasonable to order a coronary calcium scan for adults who are considered to be at intermediate risk of a heart attack over the next 10 years. A high coronary calcium score would indicate that statin therapy would likely be a useful strategy to lower that person's cardiovascular risk," study co-investigator Dr. Roger Blumenthal, director of the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University, stated in the news release.
Remarking on the research, cardiologist Dr. Vijay Nambi, an assistant professor at Baylor College of Medicine, stated that majority of insurance companies doesn’t include the calcium exams, which is valued from $200 to $400. "Sometimes people have to pay for it out of pocket," said Nambi, who thinks it's a useful test. "It helps physicians in a lot of respects."
Exam findings can also assist patients in making assessments when they're concerned regarding taking anticholesterol Canadian prescription drugs, Nambi further added.
Remcel Mae Canete together with Canada Drugs Online promotes health and fitness awareness. Know more about Remcel and Canada Drugs Online by following the link below.
Enjoy a wide range of Canadian prescription drugs at lower prices, and avail of Canadian prescriptions promos with the best Canada drugstore online!
Click here now --->>> www.CanadaDrugsOnline.com